Vedder Thinking | News Intellectual Property Team Counsels Adaptimmune in Landmark Exclusive License Deal
Vedder Price client Adaptimmune Limited has announced an exclusive commercial license agreement with Life Technologies Corporation that paves the way for the commercial development of modified T cells.
Adaptimmune’s technology is based on enhancing the power of the T cell receptor (TCR) on killer T cells. This involves taking the patient’s own T cells, genetically modifying them to present the selected TCR and then re-infusing the T cells into the patient. A critical step in this process is the stimulation and expansion of the T cells prior to re-infusion. The exclusive license deal means that Adaptimmune has secured exclusive commercial access to the technology and the underlying manufacturing processes needed for obtaining regulatory approval of the expansion of T cells carrying TCRs.
Thomas J. Kowalski, a Shareholder in the New York office of Vedder Price and a member of the firm’s Intellectual Property group, led the legal team that counseled Adaptimmune on this deal.
“We appreciate the opportunity to work with our client on this landmark license deal and help strengthen Adaptimmune’s patent portfolio,” said Vedder Price team member Deborah L. Lu, Ph.D., a Shareholder in the firm’s New York office and a member of the Intellectual Property group.
For more information, see the Adaptimmune press release.